RATIONALE: Photodynamic therapy uses a drug that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed. Photodynamic therapy using silicon phthalocyanine 4 may be effective against skin cancer. PURPOSE: This phase I trial is studying the side effects and best dose of photodynamic therapy using silicon phthalocyanine 4 in treating participants with actinic keratosis, Bowen's disease, skin cancer, or stage I or stage II mycosis fungoides.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Maximum tolerated dose
Timeframe: Treatment repeats weekly for up to 3 weeks. Cohorts of 3 participants receive escalating doses of Pc 4 and visible light until the maximum tolerated dose (MTD) is determined.
Local toxicity as measured by physical exam and punch biopsy
Timeframe: at 24 hours and 2 weeks after the start of study treatment
Treatment efficacy as measured by physical exam and punch biopsy
Timeframe: at 24 hours and 2 weeks after the start of study treatment
Systemic photosensitivity as measured by minimum erythema dose (MED) testing
Timeframe: at 2, 24, and 48 hours after completion of photodynamic therapy